Eurofins Optimed Clinical Research and Spaulding Clinical Research have formed a joint partnership agreement. The partnership is intended to leverage the strengths of both companies and facilitate collaboration on integrated clinical services to engage pharmaceutical clients that require a global footprint.

“The culture of excellence and research facilities designed to execute high-quality studies was very impressive to our team. We felt immediately comfortable with the Optimed clinical team and witnessed their efficient execution of studies,” said  Daniel Selness, Spaulding’s general manager and senior vice president of pperations.

“We were very impressed that Spaulding achieved ISO certification, which is not common among U.S. clinical research facilities. Their innovative systems approach with Electronic Data Capture is something that we have been looking to implement, so the partnership will allow us to consider how to collaborate more closely as these systems are put in place,” states Yves Donazzolo, M.D., Optimed’s chief executive officer and president.

The companies offer a range of global services to the pharma and biopharma industry, from study design through study execution/conduct, data management, statistical analysis, and medical writing. Both companies have strengths in TQT, first-in-human, multiple rising dose, bioavailability / bioequivalence, drug interaction, food effect studies and Proof-Of-Concept studies in patients.